Blueprint Medicines Corp Share Price (NASDAQ: BPMC)

$129.49

▲

0.21

(0.16%)

Last updated on July 17, 2025 at 12:00 AM IST

$₹

The stock has been delisted from the stock exchange on 17 Jul 2025

Check the interactive Blueprint Medicines Corp Stock chart to analyse performance

Blueprint Medicines Corp Key Stats

Check Blueprint Medicines Corp key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$129.28
Open	$129.5
Market Capitalization	$8.4B
Today's Volume	$3.0M
Revenue TTM	$562.1M
EBITDA	$-158.4M
Earnings Per Share (EPS)	$-2.51
Profit Margin	-27.7%
Quarterly Earnings Growth YOY	-0.99%
Return On Equity TTM	-47.71%

Global Institutional Holdings in Blueprint Medicines Corp

Name
Holdings %
Name
Holdings %
BlackRock Inc
10.38%
Vanguard Group Inc
10.27%
T. Rowe Price Associates, Inc.
8.38%
venBio Select Advisor LLC
5.95%
Wellington Management Company LLP
4.75%
State Street Corp
4.15%

Analyst Recommendation on Blueprint Medicines Corp Stock

Rating

Trend

Buy

73%Buy

17%Hold

8%Sell

Based on 23 Wall street analysts offering stock ratings for Blueprint Medicines Corp(by analysts ranked 0 to 5 stars)

Blueprint Medicines Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$66.5M	↑ 49.39%
Net Income	$-328.7M	↑ 38.9%
Net Profit Margin	-494.2%	↑ 37.33%

	FY20	Y/Y Change
Revenue	$793.7M	↑ 1093.37%
Net Income	$313.9M	↓ 195.49%
Net Profit Margin	39.54%	↑ 533.74%

	FY21	Y/Y Change
Revenue	$180.1M	↓ 77.31%
Net Income	$-644.1M	↓ 305.2%
Net Profit Margin	-357.67%	↓ 397.21%

	FY22	Y/Y Change
Revenue	$204.0M	↑ 13.3%
Net Income	$-557.5M	↓ 13.44%
Net Profit Margin	-273.24%	↑ 84.43%

	FY23	Y/Y Change
Revenue	$249.4M	↑ 22.22%
Net Income	$-507.0M	↓ 9.06%
Net Profit Margin	-203.3%	↑ 69.94%

	FY24	Y/Y Change
Revenue	$508.8M	↑ 104.04%
Net Income	$-67.1M	↓ 86.77%
Net Profit Margin	-13.19%	↑ 190.11%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$72.0M	↑ 27.21%
Net Income	$-110.9M	↓ 17.05%
Net Profit Margin	-154.14%	↑ 82.24%

	Q1 FY24	Q/Q Change
Revenue	$96.1M	↑ 33.57%
Net Income	$89.1M	↓ 180.36%
Net Profit Margin	92.74%	↑ 246.88%

	Q2 FY24	Q/Q Change
Revenue	$138.2M	↑ 43.74%
Net Income	$-50.0M	↓ 156.09%
Net Profit Margin	-36.19%	↓ 128.93%

	Q3 FY24	Q/Q Change
Revenue	$128.2M	↓ 7.22%
Net Income	$-56.3M	↑ 12.57%
Net Profit Margin	-43.9%	↓ 7.71%

	Q4 FY24	Q/Q Change
Revenue	$146.4M	↑ 14.18%
Net Income	$-50.0M	↓ 11.23%
Net Profit Margin	-34.13%	↑ 9.77%

	Q1 FY25	Q/Q Change
Revenue	$149.4M	↑ 2.08%
Net Income	$496.0K	↓ 100.99%
Net Profit Margin	0.33%	↑ 34.46%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$66.5M	↓ 133.41%

	FY20	Y/Y Change
Profit	$793.3M	↑ 1092.73%

	FY21	Y/Y Change
Profit	$162.1M	↓ 79.56%

	FY22	Y/Y Change
Profit	$186.2M	↑ 14.85%

	FY23	Y/Y Change
Profit	$236.6M	↑ 27.04%

	FY24	Y/Y Change
Profit	$488.7M	↑ 106.55%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$70.2M	↑ 34.9%

	Q1 FY24	Q/Q Change
Profit	$88.1M	↑ 25.58%

	Q2 FY24	Q/Q Change
Profit	$126.9M	↑ 44.07%

	Q3 FY24	Q/Q Change
Profit	$126.3M	↓ 0.55%

	Q4 FY24	Q/Q Change
Profit	$138.9M	↑ 10.03%

	Q1 FY25	Q/Q Change
Profit	$146.6M	↑ 5.54%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-278.0M	↑ 58.86%
Investing Cash Flow	$-16.5M	↓ 89.78%
Financing Cash Flow	$340.6M	↑ 7547.91%

	FY20	Y/Y Change
Operating Cash Flow	$387.0M	↓ 239.21%
Investing Cash Flow	$-434.2M	↑ 2537.25%
Financing Cash Flow	$617.8M	↑ 81.35%

	FY21	Y/Y Change
Operating Cash Flow	$-298.7M	↓ 177.16%
Investing Cash Flow	$-225.9M	↓ 47.99%
Financing Cash Flow	$50.7M	↓ 91.79%

	FY22	Y/Y Change
Operating Cash Flow	$-502.3M	↑ 68.18%
Investing Cash Flow	$-149.5M	↓ 33.79%
Financing Cash Flow	$561.8M	↑ 1007.76%

	FY23	Y/Y Change
Operating Cash Flow	$-436.8M	↓ 13.03%
Investing Cash Flow	$274.0M	↓ 283.25%
Financing Cash Flow	$119.2M	↓ 78.78%

	FY24	Y/Y Change
Operating Cash Flow	$-192.6M	↓ 55.91%
Investing Cash Flow	$-47.5M	↓ 117.33%
Financing Cash Flow	$273.1M	↑ 129.07%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-48.1M	↓ 52.64%
Investing Cash Flow	$-188.3M	-
Financing Cash Flow	$178.0M	↑ 165.84%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-13.6M	↓ 71.63%
Investing Cash Flow	$30.0M	↓ 115.91%
Financing Cash Flow	$18.4M	↓ 89.68%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-29.4M	↑ 115.33%
Investing Cash Flow	$33.7M	↑ 12.55%
Financing Cash Flow	$9.8M	↓ 46.9%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-54.5M	↑ 85.53%
Investing Cash Flow	$65.1M	↑ 93.06%
Financing Cash Flow	$9.2M	↓ 5.81%

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Organization	Blueprint Medicines Corp
Employees	682
CEO	Ms. Kathryn Haviland M.B.A.
Industry	Health Technology

Key Management of Blueprint Medicines Corp

Name	Title
Ms. Kathryn Haviland M.B.A.	President, CEO & Director
Mr. Alexis A. Borisy A.M.	Co-Founder & Director
Mr. Michael Landsittel CPA	Chief Financial Officer
Ms. Christina Rossi M.B.A.	Chief Operating Officer
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer
Dr. Fouad Namouni M.D.	President of Research & Development
Ms. Ariel Hurley	Senior Vice President of Finance and Principal Accounting Officer
Ms. Jenna Cohen	Senior Director & Head of Investor Relations
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary
Ms. Debra Durso-Bumpus	Chief People Officer

Important FAQs about investing in BPMC Stock from India :

What is Blueprint Medicines Corp share price today?

Blueprint Medicines Corp share price today is $129.49 as on July 17, 2025 at 12:00 AM IST at the close of the market. Blueprint Medicines Corp share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Blueprint Medicines Corp share?

Blueprint Medicines Corp share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Blueprint Medicines Corp stock price today, July 17, 2025 at 12:00 AM IST is trending at $129.49, lower by 0.12% versus the 52 week high.

How to invest in Blueprint Medicines Corp Stock (BPMC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Blueprint Medicines Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Blueprint Medicines Corp Shares that will get you 0.0116 shares as per Blueprint Medicines Corp share price of $129.49 per share as on July 17, 2025 at 12:00 AM IST.

What is the minimum amount required to buy Blueprint Medicines Corp Stock (BPMC) from India?

Indian investors can start investing in Blueprint Medicines Corp (BPMC) shares with as little as ₹87.492 or $1 (as of August 16, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in Blueprint Medicines Corp stock (as per the Rupee-Dollar exchange rate as on August 16, 2025). Based on Blueprint Medicines Corp share’s latest price of $129.49 as on July 17, 2025 at 12:00 AM IST, you will get 0.0772 shares of Blueprint Medicines Corp. Learn more about fractional shares .

What are the returns that Blueprint Medicines Corp has given to Indian investors in the last 5 years?

Blueprint Medicines Corp stock has given 0.0% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?

Discover More

Journey Medical Corp
$6.92
-4.68%
T-rex 2x Long Microsoft Daily Target Etf
$35.73
-1.19%
Airbnb
$125.10
+0.37%
Spirit Aerosystems Holdings, Inc.
$41.14
+0.61%
Biontech Se
$113.51
+0.72%
Heidmar Maritime Holdings Co
$1.55
-0.64%
Pembina Pipeline Corp
$36.69
-0.03%
S&p 500 Value Index Ishares
$201.65
-0.19%
Firstenergy Corp.
$43.48
-0.41%

Explore all